Type 1.5 diabetes, also known as latent autoimmune diabetes in adults (LADA), affects a significant portion of adults diagnosed with diabetes, estimated between 2% and 12% worldwide1 2. This form of diabetes combines features of both type 1 and type 2 diabetes, leading to challenges in diagnosis and management3 4. Understanding its unique characteristics is essential for timely diagnosis and appropriate treatment to reduce complications2 5.
Understanding Type 1.5 Diabetes
Type 1.5 diabetes is an autoimmune condition where the body's immune system attacks insulin-producing beta cells in the pancreas, similar to type 1 diabetes, but with a slower progression6 2. Unlike classic type 1 diabetes, which often presents abruptly in childhood or adolescence, type 1.5 diabetes typically manifests in adults aged 30 to 50 years and progresses gradually2 4. Patients initially retain some insulin production, allowing for a period without insulin therapy3 7.
This condition shares metabolic features with type 2 diabetes, such as adult onset and initial insulin independence, but its autoimmune nature aligns it more closely with type 1 diabetes8 4. The term "type 1.5 diabetes" is informal and lacks universal acceptance in clinical practice, with some experts considering it a subtype of type 1 diabetes due to its autoimmune basis2 8.
“LADA is a type of diabetes that has features of type 1 and type 2 diabetes. It's usually diagnosed in people aged 30 to 50 years old, and it is estimated that about 10% of people with diabetes have LADA. Like type 1 diabetes, LADA happens when the pancreas stops making insulin due to autoimmune destruction of insulin-producing beta cells. The onset is slower than type 1 diabetes and progressively worsens over time. It is common to misdiagnose people with type 2 diabetes when they actually have LADA. If in doubt about the type of diabetes a person has, it is important to check for autoantibodies, which are markers of type 1 diabetes. Those who present symptoms similar to type 2 diabetes but have positive antibodies actually have LADA. Like type 2 diabetes, people with LADA can be treated with non-insulin, glucose-lowering medications for years before requiring insulin for management of diabetes.”
— Neda Rasouli, MD, University of Colorado Department of Medicine4
Causes of Type 1.5 Diabetes
The primary cause of type 1.5 diabetes is autoimmune destruction of pancreatic beta cells, where antibodies target and gradually destroy insulin-producing cells2 3. Genetic susceptibility plays a significant role, with certain human leukocyte antigen (HLA) alleles increasing risk, although the genetic load in LADA is generally lighter than in classic type 1 diabetes2 9. Environmental factors such as viral infections, obesity, and psychosocial stress may trigger or accelerate the autoimmune process in genetically predisposed individuals, but definitive causes remain unclear2 810.
LADA represents a polygenic disease with both autoimmune and metabolic components, combining features of type 1 and type 2 diabetes9 . The autoimmune attack leads to progressive beta-cell dysfunction and insulin deficiency, but residual insulin secretion often persists for months to years before complete insulin dependence develops2 3.
- Autoantibodies, especially glutamic acid decarboxylase (GAD) antibodies, are commonly present and serve as markers of autoimmune activity11 2.
- Genetic factors overlap with both type 1 and type 2 diabetes but lean more toward autoimmune susceptibility12 9.
- Environmental triggers such as viral infections and stress may initiate or exacerbate beta-cell destruction2 10.
- Insulin resistance may be present but is generally less pronounced than in type 2 diabetes8 13.
- The autoimmune process in LADA progresses more slowly than in classic type 1 diabetes, allowing a longer period of residual beta-cell function6 2.
Common Symptoms
Symptoms of type 1.5 diabetes develop gradually due to the slow loss of beta-cell function and insulin production6 2. Many patients are initially asymptomatic and only discover their condition through routine blood glucose testing or when symptoms emerge3 . When present, symptoms resemble those of other diabetes types and are primarily related to high blood sugar levels (hyperglycemia) 1415.
Common symptoms include:
- Increased thirst (polydipsia) 14
- Frequent urination (polyuria) 14
- Increased hunger (polyphagia) 15
- Fatigue and blurred vision14 15
- Unintentional weight loss in some cases2 4
In some patients, diabetic ketoacidosis (DKA), a serious complication caused by insulin deficiency leading to ketone buildup and metabolic acidosis, may be the initial presentation2 10. Long-term complications such as cardiovascular disease and microvascular damage (neuropathy, retinopathy, nephropathy) develop similarly to other diabetes types16 14.
Symptoms of type 1.5 diabetes often appear only after significant beta-cell loss, making early detection challenging. Patients may initially respond to oral medications but eventually require insulin as the disease progresses2 3.
Diagnostic Process
Diagnosing type 1.5 diabetes involves confirming hyperglycemia and detecting autoimmune markers, primarily GAD antibodies, which are positive in about 70% of cases11 2. Standard blood glucose or HbA1c tests confirm diabetes but cannot differentiate its type17 18. Clinical features such as adult onset, absence of obesity, family history of autoimmune disease, and poor response to oral hypoglycemic agents suggest LADA rather than type 2 diabetes2 8.
C-peptide testing measures residual insulin production and helps distinguish LADA from type 1 diabetes, where C-peptide levels are typically very low or absent19 3. Some patients with LADA may be antibody-negative, complicating diagnosis and requiring careful clinical evaluation2 3.
Key diagnostic considerations include:
- Confirming hyperglycemia via fasting plasma glucose, HbA1c, or oral glucose tolerance test20 21.
- Testing for GAD and other islet autoantibodies to identify autoimmune diabetes6 10.
- Assessing C-peptide levels to evaluate beta-cell function19 .
- Considering clinical features such as lean body habitus, family history, and treatment response8 .
- Recognizing that antibody-negative patients may still have LADA based on clinical judgment2 .
| Diagnostic Feature | Type 1.5 Diabetes (LADA) | Type 1 Diabetes | Type 2 Diabetes |
|---|---|---|---|
| Age at onset | Usually >30 years6 2 | Usually childhood/adolescence | Usually adulthood16 14 |
| Autoantibodies presence | Positive in ~70% 112 | Positive in nearly all cases | Usually negative2 8 |
| C-peptide levels | Low-normal initially, decline over time19 3 | Very low or absent3 | Normal or high19 8 |
| Insulin dependence onset | Months to years after diagnosis2 3 | Rapid, often at diagnosis | Usually late or absent8 |
| Response to oral agents | Poor or declining8 | Poor | Usually good initially8 |
Risk of Misdiagnosis
Type 1.5 diabetes is frequently misdiagnosed as type 2 diabetes due to overlapping clinical features such as adult onset and initial insulin independence2 8. This misclassification can delay appropriate treatment, increasing the risk of complications5 22. Lack of awareness and limited access to antibody testing contribute to underdiagnosis8 .
Misdiagnosis risks include:
- Inappropriate use of oral hypoglycemic agents that may hasten beta-cell decline5 .
- Delayed initiation of insulin therapy, leading to poor glycemic control and increased risk of diabetic ketoacidosis (DKA) 210.
- Failure to screen for associated autoimmune diseases like thyroid disorders22 .
- Overlooking the need for regular monitoring of beta-cell function via C-peptide testing19 5.
- Confusion due to some LADA patients being antibody-negative, requiring clinical vigilance2 .
LADA should be a differential diagnosis for normal-weight patients with hypothyroidism and other autoimmune disorders, as well as those with deteriorating glycemic control despite the higher doses of oral treatments and the prescription of incretin mimetics5 .
Treatment and Prevention Options
Treatment of type 1.5 diabetes involves a gradual transition from lifestyle changes and oral hypoglycemic agents to insulin therapy as beta-cell function declines6 2. Early management may include carbohydrate restriction, exercise, and medications similar to those used in type 2 diabetes2 3. However, oral agents often lose efficacy over time due to progressive insulin deficiency8 .
C-peptide levels guide treatment decisions, with higher levels suggesting initial management similar to type 2 diabetes and lower levels indicating the need for earlier insulin initiation19 5. Sulfonylureas are generally discouraged in LADA as they may accelerate beta-cell failure5 . Newer agents like thiazolidinediones and DPP-4 inhibitors may help preserve beta-cell function and improve insulin sensitivity5 .
Currently, no prevention strategies exist due to the autoimmune nature of the disease11 2. Early diagnosis and treatment are crucial to delay complications and optimize outcomes2 .
- Lifestyle modifications such as diet and exercise help manage early disease2 3.
- Oral hypoglycemic agents may be effective initially but are often insufficient long-term2 8.
- Insulin therapy becomes necessary as beta-cell function deteriorates2 3.
- C-peptide testing assists in tailoring treatment and monitoring progression19 5.
- No established prevention exists; research is ongoing into immunomodulatory therapies2 23.
“Type 1.5 diabetes is a term used to describe patients who have some level of decreased insulin production due to decreased functioning of the beta cells of the pancreas. Patients with type 1.5 diabetes are able to produce some insulin, but not enough, and over time they may stop producing insulin entirely.”
— Deena Adimoolam, MD, Summit Health7
Key Takeaways
- Type 1.5 diabetes (LADA) is an autoimmune diabetes with features of both type 1 and type 2 diabetes, typically diagnosed in adults aged 30 to 50 years2 4.
- Autoimmune destruction of pancreatic beta cells leads to gradual insulin deficiency, with residual insulin production often lasting months to years2 3.
- Symptoms are similar to other diabetes types but develop slowly, often leading to misdiagnosis as type 2 diabetes2 5.
- Diagnosis requires detection of pancreatic autoantibodies (especially GAD antibodies) and assessment of C-peptide levels to evaluate beta-cell function11 19.
- Treatment begins with lifestyle changes and oral agents but usually progresses to insulin therapy as beta-cell function declines; no prevention strategies currently exist2 8.
